This study is looking into why low-dose aspirin, which is often used to prevent preeclampsia (a serious blood pressure condition during pregnancy), doesn't always work. Researchers want to understand if a specific genetic difference (called the PAR4 variant, rs773902) in your platelets (tiny blood cells that help with clotting) might explain why aspirin fails for some women. You may be able to join if you are a woman between 18 and 45 years old, have a history of preeclampsia, and took 81 mg of aspirin before 16 weeks of pregnancy in a subsequent pregnancy with at least 80% compliance. The study aims to find out if this genetic variant is linked to aspirin not working well to prevent preeclampsia. The current status of this study is unclear, and it plans to enroll 130 participants.

Study design

This is an interventional study with a planned enrollment of 130 women. The study is not specified as randomized or blinded.

What's involved

You would have platelet assays (tests that measure how your platelets work) including VerifyNow Aspirin assay, VerifyNow Base assay, platelet aggregometry, and Thromboxane A2 levels measured at baseline and 1 hour after taking a single dose of 81 mg enteric-coated aspirin.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, the allelic frequency of the PAR4 variant, is measured at study enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.